There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic obstructive pulmonary disease (COPD), according to real-world ...

Inhaled corticosteroids (ICS) are commonly prescribed for chronic obstructive pulmonary disease (COPD), but not recommended as first-line treatment unless patients have asthma/COPD overlap or frequent ...

GSK, leading the COPD market with its Trelegy Ellipta inhaler ... choosing the best therapy for each patient. "Are dry powder inhalers the key to sustainable respiratory care?" ...

The FDA is poised to issue a final decision on the approval and marketing of Yutrepia, an inhaled dry powder formulation of ...

Long-term inhaled corticosteroid (ICS) treatment in COPD patients is linked to increased adverse outcomes, including type 2 diabetes, cataracts, pneumonia, osteoporosis, and nontraumatic fractures.

Treat immediately with an inhaled short-acting beta1-agonist ... After chronic once-daily dry powder inhalation by COPD patients, pharmacokinetic steady state was reached by day 7 with no ...

Various types of inhalers, including short- and long-lasting options, are available for managing chronic obstructive pulmonary disease (COPD). A person can get a COPD inhaler through Medicare Part ...

The Spiriva Respimat inhaler is a cylindrical shaped plastic ... After chronic once-daily dry powder inhalation by COPD patients, pharmacokinetic steady state was reached by day 7 with no ...

Aim: (1) To compare the efficacy and adverse effects of treatment using nebulizers vs pressurized metered-dose inhalers (MDIs) with or without a spacer/holding chamber vs dry powder inhalers (DPIs ...

Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the U.S. Food and Drug ...

The deal to develop a sensor for Novartis' dry powder inhaler Breezhaler adds to the ... with technology companies seeking to digitise COPD management. Early last year, the Swiss pharma sealed ...

Despite the promising market growth, regulatory compliance and stringent guidelines continue to pose challenges for MDI ...